Single-inhaler triple therapy in patients with chronic obstructive pulmonary disease: a systematic review
Abstract Background Guidelines recommend that treatment with a long-acting β2 agonist (LABA), a long-acting muscarinic antagonist (LAMA), and inhaled corticosteroids (ICS), i.e. triple therapy, is reserved for a select group of symptomatic patients with chronic obstructive pulmonary disease (COPD) w...
Main Authors: | Sue Langham, Jen Lewis, Nick Pooley, Nina Embleton, Julia Langham, MeiLan K. Han, James D. Chalmers |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-11-01
|
Series: | Respiratory Research |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12931-019-1213-9 |
Similar Items
-
Impact of health technology assessment on prescribing patterns of inhaled fixed-dose combination triple therapy in chronic obstructive pulmonary disease
by: Jennifer Cook, et al.
Published: (2021-01-01) -
Inhaled Corticosteroids in Subjects with Chronic Obstructive Pulmonary Disease: An Old, Unfinished History
by: Andrea S. Melani, et al.
Published: (2024-02-01) -
A Prediction Scoring Model for the Effect of Withdrawal or Addition of Inhaled Corticosteroids in Patients with Chronic Obstructive Pulmonary Disease
by: Lee JH, et al.
Published: (2023-02-01) -
A proposal for the withdrawal of inhaled corticosteroids in the clinical practice of chronic obstructive pulmonary disease
by: Marc Miravitlles, et al.
Published: (2017-11-01) -
Adherence to Long-Acting Inhaler Use for Initial Treatment and Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Retrospective Cohort Study
by: Hee-Sook Suh, et al.
Published: (2022-12-01)